SOLUPORE · Solupore® - Enabling the Manufacture of Affordable New Treatments to Cure Cancer

There is encouraging news for cancer patients, a new treatment, cell immunotherapy, has been delivering spectacularclinical results and is a game changer because it is an entirely new way of treating cancer. Cancer immunotherapy, in whicha patient’s own immune cells are ‘armed’ by cell engineering to target and kill cancer cells, gives levels of complete responsein patients. The first cell immunotherapy drug was approved in August 2017 at a price of $475,000 per treatment. To bringthese life-changing treatments to patients and relieve the European and global healthcare burden they must becomeavailable at affordable costs. The one thing worse than failure is unaffordable success and the challenge with thesetreatments is the complex and high-cost of manufacturing. Current cell engineering methods are very expensive tomanufacture. Avectas has developed Solupore, a cell engineering technology, which delivers cargo to cells and plays acritical role in the manufacturing process. The technology works by temporarily making the cell membrane permeable andallowing cargo into the cell. Crucially, cell health and functionality are preserved while there is a significant improvement onthe process time and costs. Avectas has demonstrated that the pilot system can successfully deliver clinically relevant cargoto T cells. During this project, Avectas will scale and align Solupore to regulatory compliance enabling us to commercialiseit. The emerging and fast-growing cell immunotherapy market is set to be worth $20bn in 2020, with cell manufacturingrepresenting $5bn. Commercialisation of Solupore will take 1% of the €5bn market share by 2024 and will generate globalrevenues for Avectas, building value for the company and creating highly skilled jobs which will result in a high-value,knowledge-based EU company. There will be substantial European and global socio-economic impact on cancer patientsliving longer, better quality lives.